A new therapy to treat and prevent arthritis in joints
Treatment and prevention of osteoarthritis with an intra-articular disease-modifying regenerative therapy
This project is developing a new injection to help repair joint cartilage and stop osteoarthritis from getting worse.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Regenosine INC NIH-funded |
| Lab location | 1 site (Princeton, UNITED STATES) |
| Project ID | NIH-11170762 on NIH RePORTER |
What this research studies
Osteoarthritis is a common joint disorder that currently lacks therapies to prevent its progression or reverse cartilage loss, often leading to joint replacement surgery. This project is developing a first-in-class injection called Regenosine, which uses a special formulation of adenosine to regenerate cartilage. The goal is to offer patients a novel, disease-modifying therapy that significantly improves clinical outcomes and quality of life. Early tests in animal models have shown that this intra-articular injection can reverse and reduce the severity of osteoarthritis.
Who could benefit from this research
Good fit: Patients with established osteoarthritis who are looking for alternatives to surgery or current symptomatic treatments might be ideal candidates for future studies.
Not a fit: Patients without osteoarthritis or those seeking immediate pain relief without addressing cartilage regeneration may not directly benefit from this specific therapy.
Why it matters
Potential benefit: If successful, this therapy could offer patients a way to regenerate damaged cartilage, slow down or reverse osteoarthritis progression, and potentially avoid joint replacement surgery.
How similar studies have performed: While current therapies for osteoarthritis do not regenerate cartilage, this novel approach has shown promising results in animal models, suggesting a new direction for treatment.
Where this research is happening
Princeton, UNITED STATES
- Regenosine INC — Princeton, United States (Active)
Researchers
- Principal investigator: Angle, Siddhesh — Regenosine INC
- Study coordinator: Angle, Siddhesh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.